Bevacizumab in the treatment of HER2-negative breast cancer

Bevacizumab in the treatment of HER2-negative breast cancer

Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Be...

Full description

Bibliographic Details
Main Author:	Vito Lorusso
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-11-01
Series:	Biologics: Targets & Therapy
Online Access:	http://www.dovepress.com/bevacizumab-in-the-treatment-of-her2-negative-breast-cancer-a2633

Similar Items

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
by: M Rodgers, et al.
Published: (2011-05-01)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023-01-01)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
by: Zhengwu Sun, et al.
Published: (2020-03-01)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
by: Miguel Quintela-Fandino, et al.
Published: (2020-11-01)

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
by: Xuelei Ma, et al.
Published: (2016-01-01)

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
by: Boulaamane Lamiaa, et al.
Published: (2012-03-01)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
by: Yukinori Ozaki, et al.
Published: (2022-12-01)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
by: Abdel Kader Y, et al.
Published: (2013-06-01)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
by: Fabi Alessandra, et al.
Published: (2012-10-01)

The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis
by: Yanal Alnimer, et al.
Published: (2018-08-01)

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
by: Audrey Petitjean, et al.
Published: (2019-02-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
by: Shogo Nakamoto, et al.
Published: (2021-03-01)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
by: Fei Qu, et al.
Published: (2023-08-01)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
by: Anne-Claire Hardy-Bessard, et al.
Published: (2020-12-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer
by: Alexey V. Emshanov, et al.
Published: (2023-12-01)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
by: Ting Li, et al.
Published: (2015-01-01)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: E. V. ARTAMONOVA
Published: (2017-06-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
by: Nindo B. Punturi, et al.
Published: (2021-05-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
by: Junsha An, et al.
Published: (2022-03-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
by: Praveenkumar K Shetty, et al.
Published: (2012-01-01)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
by: Lan Shu, et al.
Published: (2022-08-01)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
by: Nadine S. van den Ende, et al.
Published: (2022-07-01)

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
by: Joseph A. Sparano, et al.
Published: (2022-02-01)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
Published: (2012-01-01)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer.
by: Praveenkumar K. Shetty, et al.
Published: (2012-01-01)

P121 Primary Chemotherapy with Bevacizumab for Locally Advanced Triple Negative Breast Cancer
by: J. Carpenter, et al.
Published: (2023-03-01)

HER2-low advanced breast cancer treatment
by: Marija Ban, et al.
Published: (2022-01-01)

Lapatinib for the treatment of HER2-overexpressing breast cancer
by: J Jones, et al.
Published: (2009-10-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)

Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer
by: Annarita Fanizzi, et al.
Published: (2023-05-01)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
by: Gijsen, M, et al.
Published: (2010)